ITC Declines Review Of Amendment in Drug Patent Investigation
May 22, 2026
May 22, 2026
WASHINGTON, May 22 (TNSFR) -- The International Trade Commission has declined to review an initial determination amending the complaint and notice of investigation in a patent dispute involving drug products containing C-type natriuretic peptide variants.
The amendment reflects respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC in Investigation No. 337-TA-1447.
The investigation began on May 8, 2025, after BioMarin Pharmaceutical Inc. . . .
The amendment reflects respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC in Investigation No. 337-TA-1447.
The investigation began on May 8, 2025, after BioMarin Pharmaceutical Inc. . . .